Browse By: Country ι Category ι Tag
Home  »  Global Markets Direct

Global Markets Direct Market Research Reports

Global Markets Direct is a leading provider of global business intelligence and market analysis. The company publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials.

At the heart of Global Markets Direct are unique databases, updated live, covering millions of rows of key information for the studied industry at a global level.

Gaucher Disease - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gaucher Disease – Pipeline Review, H2 2016, provides an overview of the Gaucher Disease (Genetic Disorders) pipeline landscape. Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung disease, fatigue and seizures. Treatment includes enzyme replacement therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gaucher Disease (Genetic Disorders), complete with analysis by stage of development, drug target,
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Female Contraception - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception – Pipeline Review, H2 2016, provides an overview of the Female Contraception (Women's Health) pipeline landscape. Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertili
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Colon Cancer - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer – Pipeline Review, H2 2016, provides an overview of the Colon Cancer (Oncology) pipeline landscape. Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy. Report Highlights Global Markets Direct'
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2500
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease – Pipeline Review, H2 2016, provides an overview of the Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline landscape. Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Pertussis (Whooping Cough) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pertussis (Whooping Cough) – Pipeline Review, H2 2016, provides an overview of the Pertussis (Whooping Cough) (Infectious Disease) pipeline landscape. Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pertussis (Whooping Cough) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease), complete with
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Hypertriglyceridemia - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides an overview of the Hypertriglyceridemia (Metabolic Disorders) pipeline landscape. Hypertriglyceridemia is a condition in which triglyceride levels are elevated. Causes include diabetes mellitus, obesity, family history and sedentary habits. Symptoms include gastrointestinal pain, difficulty breathing, memory loss, dementia, xanthelasmas and corneal arcus. Treatment includes diuretics, beta-blockers, estrogen therapy and corticosteroids. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Liver Cancer - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cancer – Pipeline Review, H2 2016, provides an overview of the Liver Cancer (Oncology) pipeline landscape. Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Cancer (Oncology), complete with ana
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2500
Progressive Supranuclear Palsy - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy – Pipeline Review, H2 2016, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape. Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications. Report Highlights Global Markets Direct's Pharmaceutical and He
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Burkholderia Infections - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia Infections – Pipeline Review, H2 2016, provides an overview of the Burkholderia Infections (Infectious Disease) pipeline landscape. Burkholderia infections are caused by Burkholderia cepacia bacteria. Symptoms include low-grade fever, progressing to much more serious conditions, including pneumonia, cough, congestion, shortness of breath, and wheezing. Predisposing factors include weakened immune system and lung diseases. Treatment includes antibiotics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkholderia Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bur
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease – Pipeline Review, H2 2016, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline landscape. Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics. Report Highlights Global Markets Direct
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2016, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape. Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes. Signs and symptoms include slowly progressive neurologic deficit, usually motor weakness, headache, generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment and seizures. Treatment in
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2500
Acute Lung Injury - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lung Injury – Pipeline Review, H2 2016, provides an overview of the Acute Lung Injury (Respiratory) pipeline landscape. Acute lung injury (ALI) is a common condition that is characterized by acute severe hypoxia that is not due to left atrial hypertension. ALI is most often seen as part of a systemic inflammatory process, particularly systemic sepsis, where the lung manifestations parallel those of other tissues. Causes of ALI include sepsis, burns, radiation, inhalation of noxious fumes and fat embolism. Symptoms include severe shortness of breath, low blood pressure, confusion and extreme tiredness Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeli
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Prosthetic joint infections - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prosthetic joint infections – Pipeline Review, H2 2016, provides an overview of the Prosthetic joint infections (Musculoskeletal Disorders) pipeline landscape. Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus and advanced HIV disease. Treatment includes antimicrobial therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prosthetic joint infections – Pipeline Review, H2 2016, provides co
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Resistant Hypertension - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Resistant Hypertension – Pipeline Review, H2 2016, provides an overview of the Resistant Hypertension (Cardiovascular) pipeline landscape. Resistant hypertension is defined as high blood pressure that remains uncontrolled despite treatment with antihypertensive agents. Causes of resistant hypertension include abnormalities in the hormones that control blood pressure, accumulation of artery-clogging plaque in blood vessels, obesity and sleep problems. This is handled by lifestyle alterations and regular medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Resistant Hypertension – Pipeline Review, H2 2016, provides comprehensive informat
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Relapsing Multiple Sclerosis – Pipeline Review, H2 2016, provides an overview of the Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline landscape. Progressive-relapsing multiple sclerosis (PRMS) refers to a pattern of relapses within primary-progressive MS (PPMS). Signs of PRMS include muscle spasms, weak muscles, dizziness, chronic pain and vision changes. Risk factors include age, family history, autoimmune diseases and smoking. Treatment includes immunosuppressant drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Relapsing Multiple Sclerosis – Pipeline Review, H2 2016, provides comprehens
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Gaucher Disease Type III - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gaucher Disease Type III – Pipeline Review, H2 2016, provides an overview of the Gaucher Disease Type III (Genetic Disorders) pipeline landscape. Gaucher disease type III also known as chronic neuronopathic Gaucher disease (subacute form of neuronopathic Gaucher disease). Symptoms include mental deterioration, ataxia, and myoclonic seizures. The cause of Gaucher disease III is the accumulation of a fatty material called glucocerebroside (also known as glucosylceramide) Treatment includes enzyme replacement therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease Type III – Pipeline Review, H2 2016, provides comprehensive inform
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Heart Transplant Rejection - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heart Transplant Rejection – Pipeline Review, H2 2016, provides an overview of the Heart Transplant Rejection (Immunology) pipeline landscape. Heart transplantation is the therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Eastern Equine Encephalitis - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eastern Equine Encephalitis – Pipeline Review, H2 2016, provides an overview of the Eastern Equine Encephalitis (Infectious Disease) pipeline landscape. Eastern equine encephalitis is a disease that is spread to humans by infected mosquitoes. Eastern equine encephalitis is caused by the eastern equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eastern Equine Encephalitis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Eas
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline therapeutics. The report provides comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 7 (Gut Homing Rece
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Charcot-Marie-Tooth Disease Type I A – Pipeline Review, H2 2016, provides an overview of the Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline landscape. Charcot-Marie-Tooth disease type 1A (CMT1A) is a type of inherited neurological disorder that affects the peripheral nerves. Symptoms include distal weakness and atrophy, sensory loss, foot deformities, and slow nerve conduction velocity. The disorder is caused by a duplication of the PMP22 gene on Chromosome 17. Symptomatic treatment includes pain medication, physical therapy and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Charcot-Marie-Tooth Disease Type I A – P
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H2 2016’, provides in depth analysis on CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) targeted pipeline therapeutics. The report provides comprehensive information on the CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Graves Diseases - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves Diseases – Pipeline Review, H2 2016, provides an overview of the Graves Diseases (Hormonal Disorders) pipeline landscape. Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking and pregnancy. Treatment includes anti-thyroid medications, beta blockers and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves Diseases – Pipeline Review, H2 2016, provides comprehensive in
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) - Pipeline Review, H2 2016’, provides in depth analysis on Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted pipeline therapeutics. The report provides comprehensive information on the Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players in
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Western Equine Encephalitis - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Western Equine Encephalitis – Pipeline Review, H2 2016, provides an overview of the Western Equine Encephalitis (Infectious Disease) pipeline landscape. Western equine encephalitis is a disease that is spread to humans by infected mosquitoes. Western equine encephalitis is caused by the western equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Western Equine Encephalitis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wes
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016’, provides in depth analysis on Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted pipeline therapeutics. The report provides comprehensive information on the Brain Derived Neurotrophic Factor (Abrineurin or BDNF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Brain Derived Neurotrophic Factor (Abrineurin o
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Wilms Tumor (Nephroblastoma) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wilms' Tumor (Nephroblastoma) – Pipeline Review, H2 2016, provides an overview of the Wilms' Tumor (Nephroblastoma) (Oncology) pipeline landscape. Wilms' tumor or nephroblastoma is cancer of the kidneys that typically occurs in children, rarely in adults. Its common name is an eponym.Wilms' tumor is a rare kidney cancer that primarily affects children.Wilms' tumor most often occurs in just one kidney, though it can sometimes be found in both kidneys at the same time. Typical symptoms are: an abnormally large abdomen, abdominal pain, fever, nausea and vomiting, blood in the urine (in about 20% of cases) and high blood pressure in some cases. Report Highlights Global Markets Direct's Pharmace
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Pipeline Review, H2 2016’, provides in depth analysis on Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted pipeline therapeutics. The report provides comprehensive information on the Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an ov
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Bowel Dysfunction – Pipeline Review, H2 2016, provides an overview of the Opioid-Induced Bowel Dysfunction (Toxicology) pipeline landscape. Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-oesophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. Treatment includes laxatives, stool softeners, osmotic agents and opioid antagonist. Report Highlights Global Markets Dir
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) - Pipeline Review, H2 2016’, provides in depth analysis on Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted pipeline therapeutics. The report provides comprehensive information on the Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Eosinophil Peroxidase (EPO or EPX or EC 1.11.1.7) targeted the
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Keloids - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keloids – Pipeline Review, H2 2016, provides an overview of the Keloids (Keloids) pipeline landscape. Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keloids – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Keloids (Keloids),
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Bionomics Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Bionomics Ltd - Product Pipeline Review - 2016’, provides an overview of the Bionomics Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Bionomics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced fro
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Tinea pedis (Athlete Foot) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinea pedis (Athlete Foot) – Pipeline Review, H2 2016, provides an overview of the Tinea pedis (Athlete Foot) (Infectious Disease) pipeline landscape. Athlete's foot, also known as tinea pedis, is a common foot infection caused by fungi called dermatophytes. Symptoms include dry flaking skin on the soles of the feet, unpleasant foot odour and small itchy bubbles or blisters on the soles of the feet. Treatment includes antifungal medicines. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinea pedis (Athlete Foot) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Tinea pedis (Athlete Foot)
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016’, provides an overview of the Hyundai Pharmaceutical Co Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Hyundai Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections – Pipeline Review, H2 2016, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape. Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections – Pipeline Review, H2 2016, provides comprehe
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Immune Response BioPharma Inc - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Immune Response BioPharma Inc - Product Pipeline Review - 2016’, provides an overview of the Immune Response BioPharma Inc’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Immune Response BioPharma Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Merkel Cell Carcinoma - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma – Pipeline Review, H2 2016, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape. Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Stelis Biopharma Pvt Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Stelis Biopharma Pvt Ltd - Product Pipeline Review - 2016’, provides an overview of the Stelis Biopharma Pvt Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Stelis Biopharma Pvt Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Androgenic Alopecia - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Androgenic Alopecia – Pipeline Review, H2 2016, provides an overview of the Androgenic Alopecia (Dermatology) pipeline landscape. Androgeneic alopecia is a genetically determined disorder characterized by the gradual conversion of terminal hairs into indeterminate, and finally into vellus, hairs. It is an extremely common disease that affects men and women. Predisposing factors include allergies, irritants, toxins, burns, injuries, and infections. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Androgenic Alopecia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Androgenic Alopecia (Derma
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Kissei Pharmaceutical Co Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Kissei Pharmaceutical Co Ltd - Product Pipeline Review - 2016’, provides an overview of the Kissei Pharmaceutical Co Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Kissei Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome – Pipeline Review, H2 2016, provides an overview of the Middle East Respiratory Syndrome (Infectious Disease) pipeline landscape. Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS?CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome – Pipeline Revi
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Sareum Holdings Plc - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Sareum Holdings Plc - Product Pipeline Review - 2016’, provides an overview of the Sareum Holdings Plc’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sareum Holdings Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and infor
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Zika Virus Infections - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections – Pipeline Review, H2 2016, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape. Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infec
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Shionogi & Co Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Shionogi & Co Ltd - Product Pipeline Review - 2016’, provides an overview of the Shionogi & Co Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Shionogi & Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Wounds - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds – Pipeline Review, H2 2016, provides an overview of the Wounds (Dermatology) pipeline landscape. Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or feve
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016’, provides an overview of the Zydus Cadila Healthcare Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Zydus Cadila Healthcare Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is bu
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Bullous Pemphigoid - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid – Pipeline Review, H2 2016, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape. Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. If untreated, it can persist for monthsor years, with periods of spontaneous remissions and exacerbations. The disease can be fatal, particularly in patientswho are debilitated. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology), complete with analysis by stage of development, drug targe
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Alchemia Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Alchemia Ltd - Product Pipeline Review - 2016’, provides an overview of the Alchemia Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Alchemia Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from G
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ornithine-Transcarbamylase Deficiency – Pipeline Review, H2 2016, provides an overview of the Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline landscape. Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC). OTC plays an important role in the break down and removal of nitrogen the body (urea cycle). The lack of the OTC enzyme results in excessive accumulation of nitrogen, in the form of ammonia (hyperammonemia), in the blood. Symptoms include vomiting, refusal to eat, progressive lethargy, and coma. Treatment includes nitrogen scavenging agents. Report Highlig
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Array BioPharma Inc - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Array BioPharma Inc - Product Pipeline Review - 2016’, provides an overview of the Array BioPharma Inc’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Array BioPharma Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and infor
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Usher Syndrome - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Usher Syndrome – Pipeline Review, H2 2016, provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape. Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Usher Syndrome – Pipeline Review, H2 2016, provides comprehensive infor
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
CSL Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘CSL Ltd - Product Pipeline Review - 2016’, provides an overview of the CSL Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by CSL Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets D
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I – Pipeline Review, H2 2016, provides an overview of the Neurofibromatoses Type I (Genetic Disorders) pipeline landscape. Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurof
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Genethon SA - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Genethon SA - Product Pipeline Review - 2016’, provides an overview of the Genethon SA’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Genethon SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Glob
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Wilson Disease - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wilson Disease – Pipeline Review, H2 2016, provides an overview of the Wilson Disease (Genetic Disorders) pipeline landscape. Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech, swallowing and muscle stiffness. Treatment includes chelators and Vitamin E supplements. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wilson Disease – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wilson Disease (Geneti
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Hutchison MediPharma Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Hutchison MediPharma Ltd - Product Pipeline Review - 2016’, provides an overview of the Hutchison MediPharma Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Hutchison MediPharma Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Kennedy s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) – Pipeline Review, H2 2016, provides an overview of the Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline landscape. Spinal and bulbar muscular atrophy or Kennedy disease is a disorder of specialized nerve cells that control muscle movement. These nerve cells originate in the spinal cord and the part of the brain that is connected to the spinal cord Symptoms include tremors, speech difficulties, muscle weakness, muscle wastage, muscle cramps and spasms and gynaecomastia. Treatment includes balanced diet and medications to reduce muscle cramps and tremors. Report Highlights Global Markets Direct's Ph
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Immunomedics Inc - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Immunomedics Inc - Product Pipeline Review - 2016’, provides an overview of the Immunomedics Inc’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Immunomedics Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information so
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy – Pipeline Review, H2 2016, provides an overview of the Multiple System Atrophy (Central Nervous System) pipeline landscape. Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy – Pipeline Review, H2 2016, provides com
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Kymab Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Kymab Ltd - Product Pipeline Review - 2016’, provides an overview of the Kymab Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Kymab Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Mar
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Recurrent Malignant Glioma - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma – Pipeline Review, H2 2016, provides an overview of the Recurrent Malignant Glioma (Oncology) pipeline landscape. Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy Report Highlights Global Markets Direct's Pharmaceutical
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
MediaPharma srl - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘MediaPharma srl - Product Pipeline Review - 2016’, provides an overview of the MediaPharma srl’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by MediaPharma srl, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourc
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Metastatic Uveal Melanoma - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Uveal Melanoma – Pipeline Review, H2 2016, provides an overview of the Metastatic Uveal Melanoma (Oncology) pipeline landscape. Metastatic uveal melanoma is a cancer that has spread from the eye (uveal) to other parts of the body. The most common site of metastasis for uveal melanoma is the liver. Other common sites of metastasis include the lung, bones and just beneath the skin (subcutaneous). Symptoms include jaundice, itchy skin or rash, abnormally high enzymes in the liver, abdominal pain, appetite loss, nausea, and vomiting. Treatment includes surgery, chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
PharmAbcine Inc - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘PharmAbcine Inc - Product Pipeline Review - 2016’, provides an overview of the PharmAbcine Inc’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by PharmAbcine Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourc
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progressiva – Pipeline Review, H2 2016, provides an overview of the Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline landscape. Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside that constrains movement. Symptoms swellings in fibrous tissue, pain, fever, muscle ossification and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipe
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Phylogica Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Phylogica Ltd - Product Pipeline Review - 2016’, provides an overview of the Phylogica Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Phylogica Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced fro
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Hyperinsulinemia - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia – Pipeline Review, H2 2016, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape. Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pi
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Sihuan Pharmaceutical Holdings Group Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Sihuan Pharmaceutical Holdings Group Ltd - Product Pipeline Review - 2016’, provides an overview of the Sihuan Pharmaceutical Holdings Group Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sihuan Pharmaceutical Holdings Group Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nea
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Cerebral (Fatal) Malaria - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cerebral (Fatal) Malaria – Pipeline Review, H2 2016, provides an overview of the Cerebral (Fatal) Malaria (Infectious Disease) pipeline landscape. Cerebral malaria is the most dangerous and life-threatening form of malaria that affects the brain. It is caused by plasmodium falciparum, a protozoan parasite. Plasmodium gets transmitted to human via infected mosquito bites.Symptoms include fever, head ache, muscle pain, low blood pressure, coma and convulsions. Treatment includes antimalarial, antiseizure and anti inflammatory medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cerebral (Fatal) Malaria – Pipeline Review, H2 2016, provide
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016’, provides an overview of the Sumitomo Dainippon Pharma Co Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sumitomo Dainippon Pharma Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. T
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Focal Segmental Glomerulosclerosis – Pipeline Review, H2 2016, provides an overview of the Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline landscape. Focal Segmental glomerulosclerosis is a rare disease that attacks the kidney’s filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and even failure. Symptoms include proteinuria, edema, high cholesterol, high blood pressure and poor appetite. Risk factors include infection, obesity, sickle cell disease and reflux nephropathy. Treatment includes antibiotics, vitamin D supplements, and immunosuppressive drugs. Report Highlights Global Markets Direct's Pharmaceutical a
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Kyorin Pharmaceutical Co Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Kyorin Pharmaceutical Co Ltd - Product Pipeline Review - 2016’, provides an overview of the Kyorin Pharmaceutical Co Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Kyorin Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
High-Grade Glioma - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma – Pipeline Review, H2 2016, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape. High­ly gra­de glio­mas (HGG) are tumors of the cen­tral ner­vous sys­tem (CNS) that ari­sing from trans­for­med cells of the brain and spi­nal cord. Symptoms include de­ve­lop­men­tal de­lay, head­a­ches, back­a­ches, nau­sea and vo­miting, diz­zi­ness, gait dis­tur­ban­ces, im­pai­red vi­si­on, lack of con­cen­tra­ti­on, drow­si­ness, sleep dis­tur­ban­ces, Dysregulated ap­pe­ti­te, pa­ra­ly­ses and sei­zu­res. Treatment includes Chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical a
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Millennium Pharmaceuticals Inc - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Millennium Pharmaceuticals Inc - Product Pipeline Review - 2016’, provides an overview of the Millennium Pharmaceuticals Inc’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Millennium Pharmaceuticals Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The rep
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Presbyopia - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia – Pipeline Review, H2 2016, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape. Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2000
Quark Pharmaceuticals Inc - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Quark Pharmaceuticals Inc - Product Pipeline Review - 2016’, provides an overview of the Quark Pharmaceuticals Inc’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Quark Pharmaceuticals Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built us
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Vichem Chemie Research Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Vichem Chemie Research Ltd - Product Pipeline Review - 2016’, provides an overview of the Vichem Chemie Research Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Vichem Chemie Research Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Genervon Biopharmaceuticals LLC - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Genervon Biopharmaceuticals LLC - Product Pipeline Review - 2016’, provides an overview of the Genervon Biopharmaceuticals LLC’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Genervon Biopharmaceuticals LLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016’, provides an overview of the Chong Kun Dang Pharmaceutical Corp’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Chong Kun Dang Pharmaceutical Corp, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indicati
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $1500
Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, H2 2016’, provides in depth analysis on Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted pipeline therapeutics. The report provides comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overv
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Pipeline Review, H2 2016’, provides in depth analysis on Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted pipeline therapeutics. The report provides comprehensive information on the Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, H2 2016’, provides in depth analysis on Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) targeted pipeline therapeutics. The report provides comprehensive information on the Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) , targeted therapeutics, complete with analysis by
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Nonstructural Protein 4B (NS4B) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Nonstructural Protein 4B (NS4B) - Pipeline Review, H2 2016’, provides in depth analysis on Nonstructural Protein 4B (NS4B) targeted pipeline therapeutics. The report provides comprehensive information on the Nonstructural Protein 4B (NS4B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nonstructural Protein 4B (NS4B) targeted therapeutics development and features dormant and discontinued projects. G
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (M
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted pipeline therapeutics. The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocort
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016’, provides in depth analysis on Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics develo
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016’, provides in depth analysis on 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted pipeline therapeutics. The report provides comprehensive information on the 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5), targeted therapeutics, complete with analysis by indications, stage of
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2016’, provides in depth analysis on G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted pipeline therapeutics. The report provides comprehensive information on the G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report a
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1
Summary Global Markets Direct’s, ‘Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Pipeline Review, H2 2016’, provides in depth analysis on Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted pipeline therapeutics. The report provides comprehensive information on the Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactosi
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Hemagglutinin 5 (H5) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Hemagglutinin 5 (H5) - Pipeline Review, H2 2016’, provides in depth analysis on Hemagglutinin 5 (H5) targeted pipeline therapeutics. The report provides comprehensive information on the Hemagglutinin 5 (H5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hemagglutinin 5 (H5) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report features
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Interleukin 15 (IL15) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Interleukin 15 (IL15) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 15 (IL15) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 15 (IL15) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 (IL15) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report feat
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Alpha (IL 1 Alp
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 7 Receptor
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2016’, provides in depth analysis on Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted pipeline therapeutics. The report provides comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leptin Receptor (HuB219 or OB Receptor or
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of adminis
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2016’, provides in depth analysis on P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted pipeline therapeutics. The report provides comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development an
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H2 2016’, provides in depth analysis on Niemann Pick C1 Like Protein 1 (NPC1L1) targeted pipeline therapeutics. The report provides comprehensive information on the Niemann Pick C1 Like Protein 1 (NPC1L1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics development and features d
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500
Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016’, provides in depth analysis on Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) targeted pipeline therapeutics. The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) , targeted therapeutics, complete with analysis by indications, stage of devel
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $3500

Back To Top